Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0316797 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift PLOS ONE, 2025. Verfasst von Darshee Ghia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary and secondary antibody deficiencies (PAD and SAD) are amongst the most prevalent immunodeficiency syndromes, often necessitating long-term immune globulin replacement therapy (IRT). Both intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) have demonstrated efficacy in antibody deficiency. Comparative analyses of these two routes of administration are limited to nurse-administered IVIG and home therapy with self-administered SCIG. A third programmatic approach, SCIG administered by nurses in hospital-based outpatient infusion clinics, combines certain advantages of IVIG and home SCIG such as the provision of nursing support and the reduced risk of systemic reactions associated with the subcutaneous route. This cross-sectional study aimed to compare the viability and resource utilization of nurse-administered SCIG with IVIG in patients with antibody deficiency. We hypothesized that nurse-administered SCIG would require a similar amount of infusion clinic time per month as IVIG, despite more frequent dosing, due to shorter individual appointments, while maintaining high patient satisfaction. Information on infusion duration, time in the infusion chair, direct nursing time, and treatment satisfaction using the Life Quality Index was collected. Time measures for each patient were expressed as minutes/4 weeks to account for the more frequent dosing of nurse-administered SCIG compared to IVIG. We determined that the total time, infusion time, and nursing time needed to provide nurse-administered SCIG was comparable to IVIG. The more frequent dosing of SCIG was offset by the shorter times required per infusion. Patients reported favorable treatment satisfaction with both nurse-administered SCIG and IVIG. We conclude that nurse-administered SCIG may be a useful treatment modality for well-selected individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB, Canada.
- Faculty of Science, University of Alberta, Edmonton, AB, Canada.
- Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada.
- Department of Medicine, Division of Hematology, University of Alberta, Edmonton, AB, Canada.
ORCID-Profile: Darshee Ghia, Pranavi Thota, Adil Adatia
Zitieren
APA
Ghia, D., Thota, P., Ritchie, T., Rana, H., Minhas, R., Moolji, J., Ritchie, B., & Adatia, A. (2025). Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study. PLOS ONE. https://doi.org/10.1371/journal.pone.0316797
Vancouver
Ghia D, Thota P, Ritchie T, Rana H, Minhas R, Moolji J, et al. Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study. PLOS ONE. 2025. doi:10.1371/journal.pone.0316797
BibTeX
@article{Ghia2025,
author = {Ghia, Darshee and Thota, Pranavi and Ritchie, Taylor and Rana, Heli and Minhas, Ranvir and Moolji, Jalal and Ritchie, Bruce and Adatia, Adil},
title = {Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0316797}
}
EUVIMED